Operating
Non-cash lease expense
Neurocrine Biosciences Non-cash lease expense remained flat by 0.0% to $6.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 157.7%, from $2.60M to $6.70M. Over 2 years (FY 2023 to FY 2025), Non-cash lease expense shows an upward trend with a 445.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2023
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Stable levels indicate consistent lease obligations, while significant changes may reflect shifts in real estate or equipment strategy.
Detailed definition
This represents the non-cash expense associated with the use of leased assets, such as office space or equipment, under...
Peer comparison
Standard for all companies reporting under modern lease accounting standards (e.g., ASC 842).
Metric ID:
operating_operating_lease_right_of_use_asset_periodic_re_ce6fdcHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$900.00K | $10.40M | $26.80M |
| YoY Change | — | >999% | +157.7% |
Range-$900.00K – $26.80M
CAGR+445.7%
Avg YoY Growth+706.6%
Median YoY Growth+706.6%
Current Streak2+ years growth
Non-cash lease expense at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's non-cash lease expense?
- Neurocrine Biosciences (NBIX) reported non-cash lease expense of $6.70M in Q4 2025.
- How has Neurocrine Biosciences's non-cash lease expense changed year-over-year?
- Neurocrine Biosciences's non-cash lease expense increased by 157.7% year-over-year, from $2.60M to $6.70M.
- What is the long-term trend for Neurocrine Biosciences's non-cash lease expense?
- Over 2 years (2023 to 2025), Neurocrine Biosciences's non-cash lease expense has grown at a 445.7% compound annual growth rate (CAGR), from -$900.00K to $26.80M.
- What does non-cash lease expense mean?
- The non-cash accounting expense for using leased assets.